The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial.
AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs – Pharmaceutical Technology
The mid-year period marks a significant phase for horizon scanning activities that map the regulatory approval progress of innovative medicines within the EU. In May